FENC

Fennec Pharmaceuticals Inc

FENC, USA

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

https://fennecpharma.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
FENC
stock
FENC

(FENC) Price Dynamics and Execution-Aware Positioning news.stocktradersdaily.com

Read more →
FENC
stock
FENC

Risk Check: Is FENC stock safe for conservative investors - Weekly Stock Analysis & Risk Managed Investment Signals moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$14.6

Analyst Picks

Strong Buy

3

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-46.92

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Medium

14.22 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-1.30 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

High

11.98 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 55.69% of the total shares of Fennec Pharmaceuticals Inc

1.

Southpoint Capital Advisors LP

(14.6495%)

since

2025/06/30

2.

Solas Capital Management LLC

(8.0229%)

since

2025/06/30

3.

Rosalind Advisors, Inc.

(7.3501%)

since

2025/06/30

4.

BlackRock Inc

(4.4066%)

since

2025/06/30

5.

Vanguard Group Inc

(3.4748%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(2.7894%)

since

2025/07/31

7.

iShares Russell 2000 ETF

(1.9375%)

since

2025/08/31

8.

AIGH Capital Management, LLC

(1.6255%)

since

2025/06/30

9.

State Street Corp

(1.209%)

since

2025/06/30

10.

Geode Capital Management, LLC

(1.0944%)

since

2025/06/30

11.

Harbert Fund Advisors Inc

(1.0334%)

since

2025/06/30

12.

Morgan Stanley - Brokerage Accounts

(0.9134%)

since

2025/06/30

13.

Fidelity Small Cap Index

(0.842%)

since

2025/06/30

14.

Lion Point Capital, LP

(0.7032%)

since

2025/06/30

15.

iShares Russell 2000 Value ETF

(0.5354%)

since

2025/08/31

16.

Gendell Jeffrey L

(0.502%)

since

2025/06/30

17.

Northern Trust Corp

(0.4724%)

since

2025/06/30

18.

Vanguard Russell 2000 ETF

(0.4016%)

since

2025/07/31

20.

State St Russell Sm Cap® Indx SL Cl I

(0.2479%)

since

2025/08/31

21.

Charles Schwab Investment Management Inc

(0.2202%)

since

2025/06/30

22.

Schwab Small Cap Index

(0.2202%)

since

2025/07/31

23.

NT R2000 Index Fund - NL

(0.2059%)

since

2025/06/30

24.

IMC US Ultra Micro Cap

(0.1989%)

since

2025/07/31

25.

iShares Russell 2000 Growth ETF

(0.1908%)

since

2025/08/31

26.

iShares Micro-Cap ETF

(0.1905%)

since

2025/08/31

27.

Bank of New York Mellon Corp

(0.1862%)

since

2025/06/30

28.

Hartford Financial Management Inc.

(0.182%)

since

2025/06/30

29.

Jane Street Group LLC

(0.1796%)

since

2025/06/30

30.

Susquehanna International Group, LLP

(0.1683%)

since

2025/06/30

31.

Citadel Advisors Llc

(0.1681%)

since

2025/06/30

32.

NT R2000 Index Fund - DC - NL - 3

(0.1642%)

since

2025/06/30

33.

Pleiades Small Cap Equity A

(0.1509%)

since

2025/06/30

34.

Russell 2500â„¢ Index Fund F

(0.1473%)

since

2025/06/30

35.

iShares Russell 2000 Small-Cap Idx Instl

(0.1368%)

since

2025/07/31

36.

Russell 2000 Index Non-Lendable Fund E

(0.1092%)

since

2025/06/30

37.

SPDR® Russell 2000 US Small Cap ETF

(0.1018%)

since

2025/08/31

38.

EQ/2000 Managed Volatility IB

(0.097%)

since

2025/07/31

39.

Nuveen Small Cap Blend Idx R6

(0.0879%)

since

2025/07/31

40.

Bridgeway Ultra-Small Company

(0.087%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.02

EPS Estimate

0.08

EPS Difference

-0.1

Surprise Percent

-125%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(6.3)
GARP
Fair GARP(4.5)
Growth
Moderate Growth(4)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(3)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.